Identifying reliable biomarkers of aging is a major goal in geroscience. While the first generation 44 of epigenetic biomarkers of aging were developed using chronological age as a surrogate for 45 biological age, we hypothesized that incorporation of composite clinical measures of phenotypic 46 age that capture differences in lifespan and healthspan may identify novel CpGs and facilitate the 47 development of a more powerful epigenetic biomarker of aging. Using a innovative two-step 48 process, we develop a new epigenetic biomarker of aging, DNAm PhenoAge, that strongly 49 outperforms previous measures in regards to predictions for a variety of aging outcomes, including 50 all-cause mortality, cancers, healthspan, physical functioning, and Alzheimer's disease. While this 51 biomarker was developed using data from whole blood, it correlates strongly with age in every 52 tissue and cell tested. Based on an in-depth transcriptional analysis in sorted cells, we find that 53 increased epigenetic, relative to chronological age, is associated increased activation of pro-54 inflammatory and interferon pathways, and decreased activation of transcriptional/translational 55 machinery, DNA damage response, and mitochondrial signatures. Overall, this single epigenetic 56 biomarker of aging is able to capture risks for an array of diverse outcomes across multiple tissues 57 and cells, and provide insight into important pathways in aging. 58 Keywords: aging; life expectancy; biological age; epigenetic clock; DNA methylation 59 60 61 62 63 64 4 BACKGROUND 65
8 age between 1998 and 2007 is highly correlated with the change in DNAm PhenoAge between 155 these two time-points (r=0.74, p=3.2E-80, Additional file 1: Fig. S2) . 156
DNAm PhenoAge strongly relates to all-cause mortality 157
In step 3 (Fig. 1) , the epigenetic biomarker, DNAm PhenoAge, was calculated in five independent 158 large-scale samples-two samples from Women's Health Initiative (WHI) (n=2,016; and 159 n=2,191) , the Framingham Heart Study (FHS) (n=2,553), the Normative Aging Study (NAS) 160 (n=657), and the Jackson Heart Study (JHS) (n=1,747). The first four studies used the Illumina 161 450K array while the JHS employed the latest Illumina EPIC array platform. In these studies, 162
DNAm PhenoAge correlated with chronological age at r=0.66 in WHI (Sample 1), r=0.69 in WHI 163 (Sample 2), r=0.78 in FHS, r=0.62 in the NAS, and r=0.89 in JHS. The five validation samples 164 were then used to assess the effects of DNAm PhenoAge on mortality in comparison to the Horvath 165 and Hannum DNAm Age measures. DNAm PhenoAge was significantly associated with 166 subsequent mortality risk in all studies (independent of chronological age), such that, a one year 167 increase in DNAm PhenoAge is associated with a 4.5% increase in the risk of all-cause mortality 168 (Meta(FE)=1.045, Meta p=7.9E-47, Fig. 2 ). To better conceptualize what this increase represents, 169 we compared the predicted life expectancy and mortality risk for person's representing the top 5% 170 (fastest agers), the average, and the bottom 5% (slowest agers). Results suggest that those in the 171 top 5% of fastest agers have a mortality hazard of death that is about 1.62 times that of the average 172 person, i.e. your hazard of death is 62% higher than that of an average person. Further, contrasting 173 the 5% fastest agers with the 5% slowest agers, we find that the hazard of death of the fastest agers 174 is 2.58 times higher than that of the bottom 5% slowest agers (HR=1.045 11.0 /1.045 -10.5 ). 175
Additionally, both observed and predicted Kaplan-Meier survival estimates showed that faster 176 9 agers had much lower life expectancy and survival rates compared to average and/or slow agers 177 (Fig. 2). 178 As shown in Fig. 2 , the DNAm age based measures from Hannum and Horvath also related to all-179 cause mortality, consistent with what has been reported previously [16, 24, [32] [33] [34] . To directly 180 compare the three epigenetic measures, we contrasted their accuracy in predicting 10-year and 20-181 year mortality risk, using receiver operating characteristics curves. DNAm PhenoAge (adjusted 182 for age) predicts both 10-year mortality and 20-year mortality significantly better than the other 183 two measures (Additional file 1: Table S2 ). Finally, when examining a model that includes all 184 three measures (Additional file 1: Table S3 ), we find that only DNAm PhenoAge is positively 185 associated with mortality (HR=1.04, p=1.33E-8), whereas Horvath DNAm Age is now negatively 186 associated (HR=0.98, p=2.72E-2), and Hannum DNAm Age has no association (HR=1.01, 187 p=4.66E-1). 188
DNAm PhenoAge strongly relates to aging-related morbidity 189
Given that aging is believed to also influence diseases incidence/prevalence, we examined whether 190 DNAm PhenoAge relate to diverse ag-related morbidity outcomes. We observe strong associations 191 between DNAm PhenoAge and a variety of other aging outcomes using the same five validation 192 samples ( Table 2) . For instance, independent of chronological age, higher DNAm PhenoAge is 193 associated with an increase in a person's number of coexisting morbidities (=0.008 to 0.031; 194 Meta P-value=1.95E-20), a decrease in likelihood of being disease-free (=-0.002 to -0.039; Meta 195 P-value=2.10E-10), an increase in physical functioning problems value=2. 05E-13) , an increase in the risk of CHD risk (=0.016 to 0.073; Meta P-value=3. 35E-11). 197 DNAm PhenoAge and smoking 198 13 three lines of evidence suggest that DNAm PhenoAge is not simply a measure of 268 immunosenescence. First, another measure of immunosenescence, leukocyte telomere length, is 269 only weakly correlated with DNAm PhenoAgeAccel (r=-0.13 p=0.00019 in the WHI and r=-0.087, 270 P=7.6E-3 in Framingham Heart study, Additional file 1, Fig. S8 ). Second, the strong association 271 between DNAm PhenoAge and mortality does not simply reflect changes in blood cell 272 composition, as can be seen from the fact that in Additional file 1, Fig. S9 the robust association 273 remains even after adjusting for estimates of seven blood cell count measures (Meta(FE)=1. 036, 274 Meta p=5. 6E-21) . 275
DNA sequence characteristics of the 513 CpGs in DNAm PhenoAge 276
Of the 513 CpGs in DNAm PhenoAge, we find that, 41 CpGs were also in the Horvath DNAm 277
Age measure (Additional file 2: Table S6 ). This represents a 4.88-fold increase over what would 278 be expected by chance (p=8. 97E-15) . Of the 41 overlapping CpGs, the average absolute value for 279 their age correlations was r=0.40, and 31 had age correlations with absolute values in the top 20% 280 of what is found for among the 513 CpGs in the DNAm PhenoAge score. We also observed 6 281
CpGs that overlapped between the Hannum DNAm Age score and the DNAm PhenoAge score-282 five of which were also found in the Horvath DNAm Age measure. All six CpGs had extremely 283 high age correlations (half positive, half negative), with absolute values between r=0.49 and 284 r=0.76. The five CpGs that are found in all three epigenetic aging measures were: cg05442902 285 (P2RXL1), cg06493994 (SCGN), cg09809672 (EDARADD), cg19722847 (IPO8), and 286 cg22736354 (NHLRC1). 287
Finally, we conducted a functional enrichment analysis of the chromosomal locations of the 513 288
CpGs, we found that 149 CpGs whose age correlation exceeded 0.2 tended to be located in CpG 289 islands (p=0.0045, Additional file 1: Fig. S10 ) and were significantly enriched with polycomb 290 14 group protein targets (p=8.7E-5, Additional file 1: Fig. S10 ), which echoes results of epigenome 291 wide studies of aging effects [4, 42, 43] . 292
Transcriptional and genetic studies of DNAm PhenoAge 293
Using the genome-wide data from FHS and WHI, we estimated the heritability of DNAm 294
PhenoAge. The heritability estimated by the SOLAR polygenic model for those of European 295 ancestry in the FHS was ℎ 2 =0.33, while the heritability estimated for those of European ancestry 296 in WHI, using GCTA-GREML analysis [44, 45] was ℎ 2 =0.51. 297
Using the monocyte data mentioned above, as well as PBMC expression data on 2,188 persons 298 from the FHS, we conducted a more thorough transcriptional analysis to identify differential 299 expression associated with DNAm PhenoAgeAccel (Additional file 3: Table S7 ). Overall, we find 300 that genes show similar associations to chronological age and DNAm PhenoAgeAccel. DNAm 301 PhenoAgeAccel represents aging differences among same-aged individuals and is adjusted so as 302 to exhibit a correlation of r=0.0 with chronological age. Thus, this observation can be taken to 303 suggest that genes whose transcription increases with age are upregulated among epigenetically 304 older compared to epigenetically younger persons of the same chronological age (Additional file 305 1: Fig. S11 )-same applies for genes that show decreases with chronological age being 306 downregulated in epigenetically older versus younger persons of the same age. 307
Using the transcriptional data from monocytes described above (adjusting for array, sex, 308 race/ethnicity, age, and imputed cell counts), we tested for GO enrichment among genes that 309 positively associated with DNAm PhenoAge and those that negatively associated with DNAm 310 PhenoAge (Additional file 4: Table S8 ). Among those with positive aging associations 311 (overexpression among epigenetically older individuals), we observed enrichment for a number of 312 pro-inflammatory signaling pathways. These pathways included, but were not limited to: multiple 313 15 toll-like receptor signaling pathways (7, 9, 3, 2) , regulation of inflammatory response, JAK-STAT 314 cascade, response to lipopolysaccharide, tumor necrosis factor-mediated signaling pathway, and 315 positive regulation of NF-kappaB transcription factor activity. Additionally, positively associated 316 genes were also enriched for a number anti-viral response pathways-type I interferon signaling, 317 defense response to virus, interferon-gamma-mediated signaling pathway, cellular response to 318 interferon-alpha, etc. Finally, other interesting GO terms enriched among positively associated 319 genes included: response to nutrient, JAK-STAT cascade involved in growth hormone signaling 320 pathway, multicellular organism growth, and regulation of DNA methylation. 321 When testing for enrichment among genes that were negatively associated with DNAm 322 PhenoAgeAccel (decreased expression among epigenetically older persons) we observed that 323 many were implicated in processes involving transcriptional and translational machinery, as well 324 as damage recognition and repair. These included: translational initiation; regulation of 325 translational initiation; ribosomal large subunit assembly; ribosomal small subunit assembly; 326 translational elongation; transcription initiation from RNA polymerase I promoter; transcription-327 coupled nucleotide-excision repair; nucleotide-excision repair, DNA incision, 5'-to lesion; 328 nucleotide-excision repair, DNA damage recognition; DNA damage response, detection of DNA 329 damage; and regulation of DNA damage checkpoint. 330
DISCUSSION 331
Using a novel two-step method, we were successful in developing a DNAm based biomarker of 332 aging that is highly predictive of nearly every morbidity and mortality outcome we tested. The ability of our measure to predict multifactorial aging conditions is consistent with the 344 fundamental underpinnings of Geroscience research [1, 46] , which posits that aging mechanisms 345
give rise to multiple pathologies and thus, differences in the rate of aging will have implications 346 for a wide array of diseases and conditions. Further, these results answer a fundamental biological 347 question of whether differences in multi-system dysregulation (estimated using clinical phenotypic 348 age measures), healthspan, and lifespan are reflected at the epigenetic level, in the form of 349 differential DNAm at specific CpG sites. 350
The improvement over previous epigenetic biomarkers, likely comes down to the types of CpGs 351 selected for the various measures. Only 41 of the 513 CpGs in DNAm PhenoAge were shared with 352 the Horvath clock, while only five CpGs were shared between all three clocks (DNAm PhenoAge, 353 Horvath, and Hannum). In general, these CpGs did not tend to be drivers of the DNAm PhenoAge 354 score, and instead represented those with large age correlations, but lower weights. This may 355 explain the improvements of DNAm PhenoAge over previous epigenetic biomarkers of aging. 356
While the previous DNAm age estimators selected CpGs to optimize prediction of chronological 357 age, the CpGs in DNAm PhenoAge were optimized to predict a multi-system proxy of 358 physiological dysregulation (phenotypic age). In doing so, we were able to not only capture CpGs 359 that exhibited changes in DNAm with age, but also those that captured variations in risk of death 360 and disease among same aged individuals. In general, the CpGs with the highest weights in the 361 new clock did not correlate with chronological age (Additional file 1: Fig. S12 ), but instead were 362 related to the difference between phenotypic and chronological age-i.e. divergence in the rate of 363 aging. Interestingly, the CpGs that contributed the most to the DNAm PhenoAge score, tended to 364 have low age correlations. 365
While DNAm PhenoAge greatly outperformed all previous DNAm biomarkers of aging 366 (Additional file 1: Table S5 ), the utility of DNAm PhenoAge for estimating risk does not imply 367 that it should replace clinical biomarkers when it comes to informing medical and health-related 368 decisions. In fact, but perhaps not surprisingly, the phenotypic age measure used to select CpGs is 369 a better predictor of morbidity and mortality outcomes than DNAm PhenoAge. While the addition 370 of error in performing a two-step process, rather than training a DNAm predictor directly on 371 mortality may contribute, we don't believe this accounts for the difference in predictive 372 performance. In fact, a recent DNAm measure by Zhang et al. [38] was trained to directly predict 373 mortality risk, yet it appears to be a weaker predictor than both our DNAm PhenoAge measure 374 and our clinical phenotypic age measure (Additional file 1: Table S9 ). The first generation of 375 DNAm age estimators only exhibit weak associations with clinical measures of physiological 376 dysregulation [47, 48] . Physiological dysregulation, which is more closely related to our clinical 377 age measure "phenotypic age" than to chronological age, is not only the result of 378 exogenous/endogenous stress factors (such as obesity, infections) but also a result of age related 379 molecular alterations, one example of which are modifications to the epigenome. Over time, 380 dysregulation within organ systems leads to pathogenesis of disease (age-related molecular 381 changes  physiological dysregulation  morbidity  mortality) [49] . However, stochasticity 382 18 and variability exist at each of these transitions. Therefore, measures of physiological 383 dysregulation, will be better predictors of transition to the next stage in the aging trajectory (i.e. 384 morbidity and mortality) than will measures of age related molecular alterations, like DNAm 385 PhenoAge. Similarly, quantification of disease pathogenesis (cancer stage, Alzheimer's stage) is 386 likely a better predictor of mortality risk than clinical phenotypic aging measures. As a result, 387 clinical phenotypic aging measures may be preferable to epigenetic measures when the goal is risk 388 prediction, and all samples come from blood. 389
That being said, when the aim is to study the mechanisms of the aging process, DNAm measures 390 have advantages over clinical measures. First, they may better capture "pre-clinical aging" and 391 thus may be more suited for differentiating aging in children, young adults, or extremely healthy 392 individuals, for whom measures like CRP, albumin, creatinine, glucose, etc. are still fairly 393 homogenous. Second, as demonstrated, these molecular measures can capture cell and/or tissue 394 specific aging rates and therefore may also lend themselves to in vitro studies of aging, studies for 395 which blood is not available, studies using postmortem samples, and/or studies comparing aging 396 rates between tissues/cells. While the fundamental drivers of aging are believed to be shared across 397 cells/tissues, that is not to say that all the cells and tissues within an individual will age at the same 398 rate. In fact, it is more likely that individuals will vary in their patterning of aging rates across 399 tissues, and that this will have implications for death and disease risk. Relatedly, it is not known 400 how predictions based on DNAm PhenoAge measures from non-blood samples will compare to 401 phenotypic age predictions. It may be the case that various outcomes will be more tightly related 402 to aging in specific cells/tissues, rather than blood. Finally, examination of DNAm based aging 403 rates facilitates the direct study of the proposed mechanisms of aging, of which "epigenetic 404 alterations" is one of the seven hypothesized "pillars of aging" [1] . 405 19 While more work needs to be done to model the biology linking DNAm PhenoAge and aging 406 outcomes, we began to explore this using differential expression, functional enrichment, 407 heritability estimates, and network analysis. Overall, we found that CpGs that had larger increases 408 with aging tended to be located in CpG islands and enriched with polycomb group protein targets, 409 consistent with what has been reported in previous epigenome wide studies of aging effects [4, 6, 410 7, 42, 43] . While typically DNAm of CpG islands and/or polycomb recruitment is linked to 411 transcriptional silencing [50] , for the most part, we did not observe associations between DNAm 412 and expression for co-locating CpG-gene pairs-this was also true when only considering CpGs 413 located in islands. These findings may suggest that the genes annotated to the CpGs in our score 414 are not part of the link between changes in DNAm and aging. Nevertheless, we also recognize that 415 these null results could stem from the fact that 1) associations were only tested in monocytes, 2) 416 DNAm and expression represents what is present globally for each sample, rather than on a cell-417 by-cell bases, and 3) stronger associations between DNAm and gene expression levels may only 418 exist early in life. 419
Nevertheless, we do identify potentially promising transcriptional pathways when considering 420 DNAm PhenoAge as a whole. For instance, we observe that higher DNAm PhenoAge is associated 421 with increases in the activation of proinflammatory pathways, such as NF-kappaB; increased 422 interferon (IFN) signaling; decreases in ribosomal-related and translational machinery pathways; 423 and decreases in damage recognition and repair pathways. These findings are consistent with 424 previous work describing aging associated changes, comprising increases in dysregulated 425 inflammatory activation, increased DNA damage, and loss of translational fidelity. For instance, 426 there exists a large body of literature highlighting the importance of an increased low-grade pro-427 inflammatory status as a driver of the aging process, termed inflamm-aging [41, 51, 52] . IFN 428 20 signaling pathways have been shown to be markers of DNA damage and mediators of cellular 429 senescence [53] . Additionally, it has been shown that breakdown of the transcriptional and 430 translational machinery may play a central role in the aging process [54, 55] . For instance, the 431 ribosome is believed to be a key regulator of proteostasis, and in turn, aging [54, 56] . Relatedly, 432 loss of integrity in DNA damage repair pathways is considered another hallmark of the aging 433 process [57] [58] [59] . 434
In general, many of these pathways will have implications for adaptation to exogenous and 435 endogenous stressors. Factors related to stress resistance and response have repeatedly been shown 436 to be drivers of differences in lifespan and aging [60] [61] [62] [63] [64] [65] . This may partially account for our 437 findings related to smoking. In general, it is not surprising that a biomarker of aging and mortality 438 risk relates to smoking, given that life expectancies of smokers are on average ten years shorter 439 than never smokers, and smoking history is associated with a drastic increase in the risk of a 440 number of age-related conditions. However, perhaps more interestingly, we find that the effects of 441 DNAm PhenoAge on mortality appear to be higher for smokers than non-smokers, which could 442 suggest that DNAm PhenoAge represent differences in innate resilience/vulnerability to pro-aging 443 stressors, such as cigarette smoke. 444
Interestingly, we observed moderately high heritability estimates for DNAm PhenoAge. For 445 instance, we estimated that genetic differences accounted for one-third to one-half of the variance 446 in DNAm PhenoAge, relative to chronological age. In moving forward, it will be useful to identify 447 the genetic architecture underlying differences in epigenetic aging. Finally, we reported that 448 individuals' DNAm PhenoAges-relative to their chronological ages-remained fairly stable over 449 a nine-year period. However, it is unclear whether it is attributable to genetic influences, or the 450 fact that social and behavioral characteristics tend to also remain stable for most individuals. 451
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If the goal is to utilize accurate quantifiable measures of the rate of aging, such as DNAm 452
PhenoAge, to assess the efficacy of aging interventions, more work will be needed to evaluate the 453 dynamics of DNAmPhenoAge following various treatments. For instance, it remains to be seen 454 whether interventions can reverse DNAmPhenoAge in the short term. Along these lines, it will be 455 essential to determine causality-does DNAm drive the aging process, or is it simply a surrogate 456 marker of senescence? If the former is true, DNAm PhenoAge could provide insight into promising 457 targets for therapies aimed at lifespan, and more importantly, healthspan extension. 458
Conclusion 459
Overall, DNAm PhenoAge is an attractive composite biomarker that captures organismal age and 460 the functional state of many organ systems and tissues, above and beyond what is explained by 461 chronological time. Our validation studies in multiple large and independent cohorts demonstrate 462 that DNAm PhenoAge is a highly robust predictor of both morbidity and mortality outcomes, and 463 represents a promising biomarker of aging, which may prove to be beneficial to both basic science 464 and translational research. 465
METHODS 466
Using the NHANES training data, we applied a Cox penalized regression model-where the 467 hazard of aging-related mortality (mortality from diseases of the heart, malignant neoplasms, 468 chronic lower respiratory disease, cerebrovascular disease, Alzheimer's disease, Diabetes mellitus, 469 nephritis, nephrotic syndrome, and nephrosis) was regressed on forty-two clinical markers and 470 chronological age to select variables for inclusion in our phenotypic age score. Ten-fold cross-471 validation was employed to select the parameter value, lambda, for the penalized regression. In 472 order to develop a sparse phenotypic age estimator (the fewest biomarker variables needed to 473 produce robust results) we selected a lambda of 0.0192, which represented a one standard deviation 474 22 increase over the lambda with minimum mean-squared error during cross-validation (Additional 475 file 1, Fig. S13 ). Of the forty-two biomarkers included in the penalized Cox regression model, this 476 resulted in ten variables (including chronological age) that were selected for the phenotypic age 477 predictor. 478
These nine biomarkers and chronological age were then included in a parametric proportional 479 hazards model based on the Gompertz distribution. Based on this model, we estimated the 10-year 480 (120 months) mortality risk of the j-the individual. Next, the mortality score was converted into 481 units of years (Additional file 1). The resulting phenotypic age estimate was regressed on DNA 482 methylation data using an elastic net regression analysis. The penalization parameter was chosen 483 to minimize the cross validated mean square error rate (Additional file 1, Fig. S14 ), which resulted 484 in 513 CpGs. 485
Estimation of blood cell counts based on DNAm levels 486
We estimate blood cell counts using two different software tools. First, Houseman's estimation 487 method [66] was used to estimate the proportions of CD8+ T cells, CD4+ T, natural killer, B cells, 488 and granulocytes (mainly neutrophils). Second, the Horvath method, implemented in the advanced 489 analysis option of the epigenetic clock software [11, 18] , was used to estimate the percentage of 490 exhausted CD8+ T cells (defined as CD28-CD45RA-), the number (count) of naïve CD8+ T cells 491 (defined as CD45RA+CCR7+) and plasmablasts. We and others have shown that the estimated 492 The roadmap depicts our analytical procedures. In step 1, we developed an estimate of 'Phenotypic 778
Age' based on clinical measure. Phenotypic age was developed using the NHANES III as training 779
data, in which we employed a proportional hazard penalized regression model to narrow 42 780 biomarkers to 9 biomarkers and chronological age. This measure was then validated in NHANES 781 IV and shown to be a strong predictor of both morbidity and mortality risk. In step 2, we developed 782 an epigenetic biomarker of phenotypic age, which we call DNAm PhenoAge, by regressing 783 phenotypic age (from step 1) on blood DNA methylation data, using the InCHIANTI data. This 784 produced an estimate of DNAm PhenoAge based on 513 CpGs. We then validated our new 785 epigenetic biomarker of aging, DNAm PhenoAge, using multiple cohorts, aging-related outcomes, 786 and tissues/cells. In step 3, we examined the underlying biology of the 513 CpGs and the composite 787 DNAm PhenoAge measure, using a variety of complementary data (gene expression, blood cell 788 counts) and various genome annotation tools including chromatin state analysis and gene ontology 789 enrichment. 790
Fig. 2. Mortality Prediction by DNAm PhenoAge 791
A: Using five samples from large epidemiological cohorts-two samples from the Women's health 792
Initiative, the Framingham Heart Study, the Normative Aging Study, and the Jackson Heart 793 Study-we tested whether DNAm PhenoAge was predictive of all-cause mortality. The Fig.  794 displays a forest plot for fixed-effect meta-analysis, based on Cox proportional hazard models, and 795 adjusting for chronological age. Results suggest that DNAm PhenoAge is predictive of mortality 796 in all samples, and that overall, a one year increase in DNAm PhenoAge is associated with a 4.5% 797 increase in the risk of death (p=9. 9E-47) . This is contrasted against the first generation of 798 33 epigenetic biomarkers of aging by Hannum and Horvath, which exhibit less significant 799 associations with lifespan (p=1.7E-21 and p=4.5E-5, respectively). B & C: Using the WHI sample 800 1, we plotted Kaplan-Meier survival estimates using actual data from the fastest versus the slowest 801 agers (panel B). We also applied the equation from the proportional hazard model to predict 802 remaining life expectancy and plotted predicted survival assuming a chronological age of 50 and 803 a DNAm PhenoAge of either 40 (slow ager), 50 (average ager), or 60 (fast ager) (panel C). Median 804 life expectancy at age 50 was predicted to be approximately 81 years for the fastest agers, 83.5 805 years for average agers, and 86 years for the slowest agers. 806
Fig. 3. Chronological age versus DNAm PhenoAge in a variety of tissues and cells 807
Although DNAm PhenoAge was developed using methylation data from whole blood, it also 808 tracks chronological age in a wide variety of tissues and cells. A) The correlation across all 809 tissues/cells we examined is r=0.71. B-ZJ) report results in different sources of DNA as indicated 810 (MAP), we find a moderate/high correlation between chronological age and DNAm PhenoAge 816 (panl A), that is further increased after adjusting for the estimated proportion on neurons in each 817 sample (panel C). We also find that DNAm PhenoAge is significantly higher (p=0.00046) among 818 those with Alzheimer's disease versus controls (panel D), and that it positively correlates with 819 amyloid load (p=0.012, panel E), neuritic plaques (p=0.0032, panel F), diffuse plaques (p=0.036, 820 panel G), and neurofibrillary tangles (p=0.0073, panel H).
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